Guggenheim Maintains Buy on Jade Biosciences, Lowers Price Target to $41
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Guggenheim analyst Vamil Divan maintains Jade Biosciences (NASDAQ:JBIO) with a Buy and lowers the price target from $47 to $41.
Guggenheim analyst Vamil Divan maintains Jade Biosciences (NASDAQ:JBIO) with a Buy and lowers the price target from $47 to $41.
